Topotecan Monotherapy in Heavily Pretreated Patients with Progressive Advanced Stage Neuroendocrine Carcinomas

@inproceedings{Olsen2014TopotecanMI,
  title={Topotecan Monotherapy in Heavily Pretreated Patients with Progressive Advanced Stage Neuroendocrine Carcinomas},
  author={Ingrid Holst Olsen and Ulrich Peter Knigge and Birgitte Hartnack Federspiel and Carsten Paln{\ae}s Hansen and Anna Skov and Andreas Kj{\ae}r and Seppo Wang Langer},
  booktitle={Journal of Cancer},
  year={2014}
}
BACKGROUND Neuroendocrine carcinomas (WHO grade 3) are highly aggressive tumors with an immense tendency to metastasize and with a poor prognosis. In advanced disease, there is no standard treatment beyond first-line platin/etoposide-based chemotherapy. Topotecan is widely used as second-line treatment in small cell lung cancer, which also responds markedly on first-line platin/etoposide. Hence, we investigated the feasibility of topotecan in previously treated patients with neuroendocrine… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 11 references

Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2006
View 5 Excerpts
Highly Influenced

One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2008
View 1 Excerpt

Topotecan: An evolving option in the treatment of relapsed small cell lung cancer

Therapeutics and clinical risk management • 2007
View 1 Excerpt

Similar Papers

Loading similar papers…